Se ob

FORM ·	4
--------	---

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

			01.060		vesiment con	Iparty Act of 1940					
1. Name and Address of Reporting Person <sup>*</sup> <u>LARUE WILLIAM R</u>				er Name <b>and</b> Ticker ENCE PHAF { ]		<sup>ymbol</sup> T <u>ICALS INC</u> [		tionship of Reportin all applicable) Director Officer (give title below)	suer )wner (specify		
(Last) (First) (Middle)				of Earliest Transac	tion (Month/D	ay/Year)	1	SVP, CFO, Treas, Asst Sec			
C/O CADENCE PHARMACEUTICALS, INC.			03/16/	2011				3 3	,		
12481 HIGH BLUFF DRIVE, SUITE 200											
			4. If Am	endment, Date of C	Driginal Filed (	Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) SAN DIEGO CA 92130							X	Form filed by One	e Reporting Perso	on	
								Form filed by More than One Reporting			
-						Person					
(City)	(State)	(Zip)									
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1. Title of Security (Instr. 3) 2. Transa Date				2A. Deemed Execution Date.	3. Transaction	4. Securities Acquired (A) Disposed Of (D) (Instr. 3.4		5. Amount of Securities	6. Ownership Form: Direct	7. Nature of	

Code V Amount (A) or (D) Price Transaction(s) (Instr. 3 and 4) (Instr. 4)	(Month/Day/Year)	if any (	Transa Code (I 8)		Disposed Of ( 5)	D) (Instr.	3, 4 and	Beneficially	Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial Ownership (Instr. 4)	
			Code	v			Price	Transaction(s)		(Instr. 4)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Derivative		of 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
stock option (right to buy)	<b>\$</b> 8.55	03/16/2011		A		125,000		(1)	03/16/2021	common stock	125,000	(2)	125,000	D	

Explanation of Responses:

1. 25% of the number of shares of common stock subject to the option vest one year after the date of grant, and 1/48th of the original number of shares of common stock subject to the option vest on the first day of each full month thereafter.

2. Not applicable to this transaction.

**Remarks:** 

## Hazel M. Aker Attorney-in-fact 03/18/2011

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.